Capital One at 9.4% and Five Other Banks: Inside Chris Davis's $22B Financials-First Q4 2025 Portfolio

When most institutional portfolios read like a who's-who of Silicon Valley, Davis Selected Advisers does something almost contrarian by default: it puts a regional bank at the top of the sheet. Capital One Financial at 9.4% of a $22.25 billion portfolio isn't just a large position—it's larger than most funds' entire financial-sector allocation. And COF is only the headliner. Add U.S. Bancorp, Wells Fargo, Berkshire Hathaway, Markel, and Chubb, and you're looking at roughly 32 cents of every dollar Chris Davis manages parked in financial stocks.

That's not an accident. It's a dynasty-level conviction that traces back three generations—from grandfather Shelby Davis, who turned $100,000 into $800 million buying insurance stocks in the 1940s, to Chris himself, who sits on Berkshire Hathaway's board of directors and preaches that "growth is a component of value."

Here's what changed in Q4 2025, and what it tells us about where this third-generation value investor sees opportunity.

TL;DR — Davis Selected Q4 2025

• AUM: $22.25B across 108 holdings, up from $19.15B in Q3 (+16.2%)
• Capital One (COF) remains the #1 position at 9.4%, a conviction bet held for years
• Financials dominate: ~32% of portfolio across banks, insurers, and financial infrastructure
• Big adds: Coterra Energy (CTRA) surged from 2.5% → 3.8% weight; USB, GOOGL, VTRS all saw 12%+ share increases
• Profit-taking: Meta (META) trimmed from 6.6% → 5.2%; Applied Materials cut by 24% of shares
• Healthcare rotation: Exited Humana entirely while adding to CVS and Viatris
• New bets: JBS ($171M debut) marks a first foray into global protein; Fiserv (FISV) added
• Q4 performance: +9.17%, outperforming many peers

Filing Snapshot

The Capital One Conviction: Why 9.4% in a Single Bank

A 9.4% allocation to Capital One Financial (COF)—worth $2.09 billion—isn't a passive index weight. It's a deliberate, high-conviction bet that COF is mispriced relative to its earnings power. At $2.09B, this single position is larger than the entire AUM of many mid-size hedge funds.

Chris Davis has held COF as his top position for years, weathering credit-cycle fears and fintech disruption narratives. The thesis likely centers on COF's technology-first approach to banking (it runs entirely on cloud infrastructure), its growing credit card franchise, and a valuation that still trades at a discount to money-center banks despite superior digital capabilities.

The stability here is the story: COF moved from 9.3% to 9.4% quarter-over-quarter. Davis isn't trading around this position. He's sitting on it—the kind of patience his grandfather would recognize.

The Financials Empire: 32% and Growing

Capital One is the crown jewel, but the financials portfolio is a diversified monarchy:

The pattern is unmistakable: Davis doesn't just own banks—he owns the entire financial value chain. Consumer banks (COF, USB), money-center banks (WFC), insurance holding companies run like mini-Berkshires (MKL), property & casualty insurers (CB), and digital disruptors (ALLY). It's a bet on the financial system itself.

U.S. Bancorp was a notable add in Q4, with shares increasing 13.4% and value jumping 25.2% to $1.18B. Davis is clearly building conviction that USB's conservative lending culture and dividend yield make it an underappreciated compounder.

Healthcare Rotation: Exit Humana, Double Down on Value

The healthcare moves in Q4 tell a coherent story. Davis completely exited Humana (HUM)—a managed-care insurer facing headwinds from rising medical costs and Medicare Advantage rate pressure—while simultaneously increasing positions in:

• CVS Health (CVS): Added 11.9% more shares, bringing weight to 4.6% ($1.01B). CVS's integrated pharmacy-benefits-retail model trades at a deep value multiple.
• Viatris (VTRS): Added 12.7% more shares, weight jumping from 3.6% → 4.4% ($973M). The generic-drug maker is a classic Davis-style play: hated by the market, generating significant free cash flow.
• Solventum (SOLV): Maintained at 2.2% ($493M). The 3M healthcare spinoff is still finding its footing as an independent company.

The message: Davis hasn't lost faith in healthcare. He's rotating from managed care (where margins are compressing) into pharma distribution and generics (where valuations are more attractive).

The Coterra Surge and Energy Positioning

Coterra Energy (CTRA) saw the most dramatic increase in Q4, surging from 2.5% to 3.8% weight with $386M in added value (+82.1%). This isn't a small trim-and-add—it's a major conviction increase in a natural gas and oil E&P company.

Paired with Teck Resources (TECK) at 2.6% and ConocoPhillips (COP) at 0.8%, Davis has roughly 8% in energy and materials. The Coterra bet in particular looks like a play on rising natural gas demand from AI data centers and LNG exports—a thesis that's gaining traction across the institutional landscape.

Meta Profit-Taking: The Tech Trim

Meta Platforms dropped from 6.6% to 5.2% as Davis reduced shares. Applied Materials (AMAT) saw a more aggressive 24.4% share reduction, dropping from 5.9% to 4.9%. Bank of New York Mellon (BK) was trimmed by 48.4% of shares.

This isn't a tech exodus—Meta and AMAT remain top-5 holdings. But the direction is clear: Davis is harvesting gains from positions that have appreciated significantly and redeploying into cheaper names. It's textbook value discipline: sell what's expensive, buy what's cheap.

Even after trimming, tech still represents roughly 14% of the portfolio through Meta, Applied Materials, Alphabet, Amazon, Texas Instruments, and Pinterest.

New Position: JBS and the Protein Thesis

Perhaps the most intriguing Q4 move was a brand-new $171M position in JBS S.A., the Brazilian-headquartered global meat and protein giant. At 0.8% of portfolio, it's a starter position—but a meaningful one at $171 million.

JBS is the world's largest protein company by sales, operating across beef, poultry, and pork on multiple continents. The stock trades at a significant discount to U.S. peers like Tyson Foods (TSN, already a 3.4% position for Davis). The JBS addition alongside the existing Tyson stake suggests Davis sees structural value in global food production—a sector with high barriers to entry and growing emerging-market demand.

Other new positions include Fiserv (FISV) at $38M (a payments-technology company that fits the financials thesis) and CubeSmart (CUBE), a self-storage REIT.

The Third-Generation Edge

Understanding Davis Selected requires understanding the Davis family. Shelby Davis started with insurance stocks in the 1940s and compounded $100,000 into $800 million. His son, Shelby M.C. Davis, broadened into all sectors. Chris Davis—the third generation—now manages over $22 billion with a philosophy forged across eight decades of family investing wisdom.

Chris sits on Berkshire Hathaway's board of directors, giving him direct access to Warren Buffett's thinking. His mantra—"growth is a component of value"—rejects the false dichotomy between growth and value investing. He argues all investing is value investing; the only question is whether you're paying a fair price for future cash flows.

That philosophy explains the portfolio's shape: Capital One isn't a "value trap"—it's a technology company disguised as a bank. Meta isn't a "growth stock"—it's a cash-flow machine trading at a reasonable multiple. The labels don't matter to Davis. The math does.

Exits and What They Signal

Three complete exits round out the Q4 picture:

• Humana (HUM): Managed care under pressure from rising medical costs—Davis chose to exit entirely rather than hold through uncertainty.
• Restoration Hardware (RH): Luxury home furnishings. Davis apparently decided the turnaround thesis had played out or stalled.
• Hudson Pacific Properties (HPP): Office REIT concentrated in San Francisco and LA—two markets still struggling with post-pandemic office demand.

Each exit reflects discipline: when the thesis breaks, sell completely. Don't hold on hoping.

Frequently Asked Questions

Why does Chris Davis have nearly 10% in Capital One?

Davis views Capital One as a technology company that happens to be a bank. COF runs entirely on cloud infrastructure, has a growing credit card franchise, and trades at a discount to peers despite superior digital capabilities. The position has been his top holding for years, reflecting deep conviction in COF's long-term earnings power.

Is 32% in financials too concentrated?

For most funds, yes. For Davis, it's a family tradition. His grandfather Shelby Davis built his fortune on insurance stocks. Chris diversifies within financials—consumer banks, regional banks, insurance, fintech—rather than spreading thin across every sector. The concentration reflects where he sees the best risk-adjusted value.

Why did Davis exit Humana but keep CVS and Viatris?

Humana faces specific headwinds in Medicare Advantage rates and rising medical costs that pressure margins. CVS and Viatris operate in different parts of healthcare—pharmacy distribution and generics—where valuations are more attractive and cash-flow generation is more predictable. It's a rotation within healthcare, not an exit from it.

What does the Coterra Energy increase signal?

The aggressive Coterra add (+82% value increase) suggests Davis sees value in natural gas exposure. Rising demand from AI data centers, LNG exports, and energy security concerns all support the thesis. At 3.8% of portfolio, it's now a top-10 holding—a clear signal of conviction.

Should retail investors copy this portfolio?

No portfolio should be copied blindly. Davis manages $22B with a multi-decade time horizon and family legacy considerations. However, studying his moves can highlight underappreciated value opportunities. The financials concentration, in particular, represents a contrarian bet against the tech-heavy consensus that retail investors may want to evaluate independently.

How did Davis perform in Q4 2025?

The portfolio returned +9.17% in Q4 2025, outperforming many institutional peers. The combination of financial sector strength, energy gains from Coterra, and disciplined profit-taking in tech contributed to the strong quarter.